| 4.97 0 (0%) | 06-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.87 | 1-year : | 6.86 |
| Resists | First : | 5.03 | Second : | 5.87 |
| Pivot price | 4.86  |
|||
| Supports | First : | 3.89 | Second : | 3.2 |
| MAs | MA(5) : | 4.97  |
MA(20) : | 4.55 |
| MA(100) : | 5.19 |
MA(250) : | 10.03 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 96.7 |
D(3) : | 97.2 |
| RSI | RSI(14): 62.8 | |||
| 52-week | High : | 28.6 | Low : | 3.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BLUE ] has closed below upper band by 43.8%. Bollinger Bands are 22.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.97 - 5.01 | 5.01 - 5.04 |
| Low: | 4.9 - 4.94 | 4.94 - 4.97 |
| Close: | 4.92 - 4.98 | 4.98 - 5.02 |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Mon, 02 Jun 2025
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital - Business Wire
Mon, 02 Jun 2025
Bluebird Bio (BLUE) Acquired by Carlyle and SK Capital Partners | BLUE Stock News - GuruFocus
Mon, 02 Jun 2025
bluebird bio acquired to scale gene therapy access - Investing.com
Tue, 27 May 2025
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital - Business Wire
Wed, 14 May 2025
Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity - Yahoo Finance
Fri, 09 May 2025
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 39.6 (%) |
| Shares Short | 281 (K) |
| Shares Short P.Month | 507 (K) |
| EPS | -20.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.91 |
| Profit Margin | -192.4 % |
| Operating Margin | -55.6 % |
| Return on Assets (ttm) | -28.4 % |
| Return on Equity (ttm) | -546.6 % |
| Qtrly Rev. Growth | 108.4 % |
| Gross Profit (p.s.) | 2.87 |
| Sales Per Share | 10.61 |
| EBITDA (p.s.) | -15.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -229 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -0.25 |
| PEG Ratio | 0 |
| Price to Book value | -0.85 |
| Price to Sales | 0.46 |
| Price to Cash Flow | -0.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|